UBS Group
NAMS icon

UBS Group’s NewAmsterdam Pharma NAMS Stock Holding History

UBS Group’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.7M Sell
344,065
-450,911
-57% -$14.9M ﹤0.01% 3279
2026
Q1 		$25.4M Sell
794,976
-104,466
-12% -$3.4M ﹤0.01% 2332
2025
Q4 		$31.6M Buy
899,442
+130,922
+17% +$4.76M 0.01% 2123
2025
Q3 		$21.9M Buy
768,520
+140,801
+22% +$3.38M ﹤0.01% 2467
2025
Q2 		$11.4M Buy
627,719
+229,576
+58% +$4.19M ﹤0.01% 2953
2025
Q1 		$8.15M Buy
398,143
+317,933
+396% +$7.07M ﹤0.01% 3265
2024
Q4 		$2.06M Sell
80,210
-50,030
-38% -$1.06M ﹤0.01% 4687
2024
Q3 		$2.16M Buy
130,240
+124,171
+2,046% +$2.15M ﹤0.01% 3911
2024
Q2 		$117K Sell
6,069
-42,210
-87% -$847K ﹤0.01% 6075
2024
Q1 		$1.14M Buy
48,279
+47,479
+5,935% +$964K ﹤0.01% 4490
2023
Q4 		$8.94K Buy
+800
New +$7.33K ﹤0.01% 7519
2023
Q3 		– Sell
-183
Closed -$2.18K – 9798
2023
Q2 		$2.18K Buy
+183
New +$2.43K ﹤0.01% 7799

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

UBS Group's NAMS Position: Q2 2026 in Review

UBS Group reduced its NewAmsterdam Pharma (NAMS) stake by 57% in Q2 2026, selling an estimated $14.9M and leaving 344,065 shares worth $11.7M. The position accounts for ﹤0.01% of the portfolio, ranked #3279.

UBS Group first reported a position in NAMS in Q2 2023 and has held it in 12 quarters since. The position peaked at $31.6M in Q4 2025. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • UBS Group held 344,065 shares of NewAmsterdam Pharma worth $11.7M as of Q2 2026.
  • UBS Group sold 450,911 NewAmsterdam Pharma shares in Q2 2026, an estimated $14.9M.
  • NewAmsterdam Pharma made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3279 holding.
  • UBS Group first reported a position in NewAmsterdam Pharma in Q2 2023 and has held it in 12 quarters since.
  • UBS Group's NewAmsterdam Pharma position peaked at $31.6M in Q4 2025.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.